Related Experiment Videos
Hormone therapy for locally advanced prostate cancer
Jackson E Fowler1, Steven A Bigler, Paige C White
1Division of Urology and Department of Pathology, University of Mississippi School of Medicine and Section of Urology, Veterans Affairs Medical Center, Jackson, Mississippi, USA.
The Journal of Urology
|July 20, 2002
Summary
Hormone therapy for advanced prostate cancer shows good survival rates with low tumor-related morbidity. Competing diseases significantly impact overall survival, highlighting the importance of patient health status.
Area of Science:
- Oncology
- Urology
- Geriatric Medicine
Background:
- Locally advanced prostate cancer requires effective treatment strategies.
- Hormone therapy is a common approach for managing advanced prostate cancer.
Purpose of the Study:
- To evaluate cause-specific and all-cause survival in men with locally advanced prostate cancer receiving hormone therapy.
- To assess the morbidity associated with hormone therapy in this patient population.
Main Methods:
- A cohort of 208 men with locally advanced prostate cancer were treated with androgen ablation or combined androgen ablation and antiandrogen therapy.
- Follow-up data was collected over a median observation period of 46 months.
- Survival and morbidity outcomes were analyzed, considering demographic and clinical variables.
Main Results:
- Cause-specific survival at 5 and 8 years was 92% and 80%, respectively.
- All-cause survival at 5 and 8 years was 59% and 41%, respectively.
- Gleason score and comorbidity score were significant predictors of cause-specific and all-cause survival, respectively. Morbidity was low.
Conclusions:
- Hormone therapy for locally advanced prostate cancer is associated with minimal tumor and treatment-related morbidity.
- All-cause survival outcomes are comparable to those seen with combined hormone and radiation therapy.